MedPath

A verification study of the anti-obesity effects of the test food consumptio

Not Applicable
Conditions
Healthy Japanese subjects
Registration Number
JPRN-UMIN000050201
Lead Sponsor
ORTHOMEDICO Inc.
Brief Summary

Not available

Detailed Description

Not available

Recruitment & Eligibility

Status
Complete: follow-up complete
Sex
All
Target Recruitment
68
Inclusion Criteria

Not provided

Exclusion Criteria

1. Subjects who are undergoing medical treatment or have a medical history of malignant tumor, heart failure, and myocardial infarction 2. Subjects who have a pacemaker or an implantable cardioverter defibrillator (ICD) 3. Subjects currently undergoing treatment for any of the following chronic diseases: cardiac arrhythmia, liver disorder, kidney disorder, cerebrovascular disorder, rheumatism, diabetes mellitus, dyslipidemia, hypertension, or any other chronic diseases 4. Subjects who have severe anemia 5. Subjects who drink a large amount of alcohol or excessively smoke 6. Subjects whose life rhythms are irregular due to working a late-night shift or others 7. Subjects who intensely exercise 8. Subjects who use or take "Foods for Specified Health Uses," or "Foods with Functional Claims" in daily 9. Subjects who are currently taking medications (including herbal medicines) and supplements 10. Subjects who are allergic to medicines and/or the test food related products 11. Subjects who are pregnant, lactating, or planning to become pregnant during this trial 12. Subjects who suffer from COVID-19 13. Subjects who have been enrolled in other clinical trials within the last 28 days before the agreement to participate in this trial or plan to participate another trial during this trial 14. Subjects who are judged as ineligible to participate in this study by the physician

Study & Design

Study Type
Interventional
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
1. The abdominal visceral fat area at 12 weeks after consumption (12w)
Secondary Outcome Measures
NameTimeMethod
1. The abdominal visceral fat area at four and eight weeks after consumption (4w and 8w), and at four weeks after completed consumption (a4w) 2. The abdominal total fat area, the abdominal subcutaneous fat area, body weight, body mass index (BMI), body fat percentage, fat mass, muscle mass, abdominal circumference, waist circumference, hip circumference at 4w, 8w, 12w, and a4w
© Copyright 2025. All Rights Reserved by MedPath